Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06636552
Title An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L (EUMELEIA)
Acronym EUMELEIA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hellenic Society of Hematology
Indications
Therapies
Age Groups: senior | adult
Covered Countries GRC

Facility Status City State Zip Country Details
1st Propaedeutic Department, "Laiko" General Hospital of Athens RECRUITING Athens Attica Greece Details
Hematology Clinic, General Hospital of Athens "Evanggelismos" RECRUITING Athens Attica Greece Details
Hematology Department "Alexandra" General Hospital of Athens RECRUITING Athens Attica Greece Details
Hematology Department, University General Hospital of Alexandroupolis RECRUITING Alexandroupolis Evros Greece Details
Hematology Department, Regional General Hospital for Cancer Treatment "Metaxa" of Piraeus RECRUITING Piraeus Greece Details
Hematology Department, General Hospital of Thessaloniki "Papanikolaou" RECRUITING Thessaloniki Greece Details
Hematology Department, Theageneion Cancer Hospital RECRUITING Thessaloniki Greece Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field